SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AFFYMETRIX (AFFX) -- Ignore unavailable to you. Want to Upgrade?

To: TEColeman who wrote (577)12/9/1997 9:20:00 PM
From: Bill Holtzman  Read Replies (1) | Respond to of 1728
 
For what it's worth, Fidelity Biotech Fund owns 100,000 shares of Hyseq and no AFFX.



To: TEColeman who wrote (577)12/10/1997 2:28:00 AM
From: JF Quinnelly  Read Replies (1) | Respond to of 1728
 
Maybe Hyseq thinks it will be easier to make money by suing Affymetrix than by selling their own product. Seems to me that Nanogen has looked like a more formidable rival to Affymetrix than Hyseq, but then this field moves pretty fast. I wonder if this suit has much merit?

Here's a post that might be of interest:

techstocks.com


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News